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It  has  been  previously  established  in  this  laboratory  that  sera  from  CBA mice 
made tolerant to A/Jax skin grafts (neonatally induced tolerance) were able to enhance 
the growth of A/Jax tumors grafted on otherwise untreated CBA mice. This property 
was specifically removed by incubation with A cells (and not by CBA cells).  The sera 
included  those  from highly tolerant mice, even taken  before skin grafting, and  the 
criteria for tolerance were severe,  skin grafts in perfect state  100 days after grafting 
(1, 2). 
These  and other  data  demonstrated  the state  of immune  reactivity of lymphoid 
tissue from tolerant animals toward tolerated cells (1-4) as well as the establishment 
of a  state  indistinguishable  from  that  of immunological  tolerance  through  immu- 
nological  facilitation  enhancement  in  the  graft-versu3-host situation  (5-9).  These 
results confirmed our views according to which immunological facilitation  (the basis 
for the mechanisms of immunological enhancement) is also the basis for the mechanism 
of immunological tolerance of living cells (4, 10), implying an active immune reaction 
followed by an antibody mediation of some crucial step. Further confirmation came 
from converging evidence obtained in other laboratory experiments  (11-18). 
The purpose  of the present  work  was to obtain  some more precise  data  on 
the properties,  time evolution, and nature of the antibodies responsible for the 
selective inlmunosuppression that we believe leads to the state of immune toler- 
ance to living cells (19). It consisted in studying the sera of highly tolerant  mice 
as  compared with  those  of corresponding normal  and  immune  mice for their 
content in immunoglobulins of the different classes, in immuno-sero-biological 
activities,  and  in facilitation-enhancing  antibodies  (able  to  transfer  tolerance 
to corresponding allografted tumors). Evolution of the two last types of proper- 
ties was studied in mice followed from birth (and tolerance induction)  to sacri- 
fice (in a  state of high tolerance),  looking for modifications brought in the im- 
mune status by the time and by the allograft procedures. We also tried to elute 
specific antibodies from spleens  of highly tolerant  animals.  Finally,  sera  (tol- 
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erant,  immune, or normal) were fractionated on chromatography  columns  and 
the resulting fractions were studied for their content in immunoglobulins of the 
different  classes,  in  immuno-sero-biological  activities,  and  in  facilitation-en- 
hancing  properties.  Links  between  biological  properties  and  immunog[obulin 
classes were looked for. 
Materials  and Methods 
Animals.--CBA and A strain mice and their Ft hybrids were bred in our laboratory as pre- 
viously stated (1, 2, 9). 
A/Jax Tumors.--Sarcoma  I  was  obtained from Dr. L Hilgert, Institute of Experimental 
Biology and Genetics, Praha, Czechoslovakia, and kept since 1969 in ascitic form in A strain 
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FIG.  1.  "rime schedule of blood withdrawal from tolerant animals and the constitution of 
three different serum pools, Only sera from highly tolerant animals (skin graft looking like an 
isograft at sacrifice time) entered the pools. 
animals. This sarcoma has proved in our laboratory to be more susceptible to enhancement in 
CBA strains than other SaI substrains. On the other hand, it gives up  to  33%  of  takes  in 
normal CBA mice, 
Sarcoma 15091a was obtained by courtesy of Dr. N. Kaliss and kept in our laboratory since 
1970 in A strain mice. It gives no take in normal CBA mice but is relatively less susceptible 
to enhancement. 
Induction and Evaluation  of Tolerance.--Tolerance  to A strain tissue was induced in CBA 
newborn mice by intravenous injections of 15 X  106 (CBA X  A) Ft spleen cells. For evaluation, 
mice were grafted at 8 wk with A skin (1, 2) and grafts were inspected weekly and recorded 
for their general aspect. Only grafts which did not present any rejection signs, thus closely 
resembling isografts, were kept for tolerant serum experiments. Each animal was numbered 
and followed individually. Mice having a perfect state of graft over 100 days were considered 
as highly tolerant, 
Serum Cotlection.--Blood  samples were drawn from the tail artery after heating the animals 
at 37°C.  A record indicating the animal's number and time of blood collection was entered for 
each bleeding. Only samples from highly tolerant mice were pooled and used for the experiments 
presented. G.  A.  VOISIN~  R.  G.  KINSKY~ AND  It.  T.  DUC  1187 
Three pools were prepared (Fig. i): I, before skin grafting; II, 2 wk after skin grafting and 
regular bleedings until day 80 after the graft; III, exsanguinafion at sacrifice, at the end of 
the 4th month. 
Extraction  of Antibodies  from Spleens  of Tolerant Mice.--Spleens were stored at  --70°C, 
thawed at room temperature, and individually ground in a loose Potter-Elvehjem grinder in 
0.5 ml of saline. The suspension was heated at 46°C for 30 min under continuous moderate 
shaking. The supernatant of a  5 rain centrifugation (500 g at 46°C) was mixed with dextran 
(3 volumes of 6% intradex for 7 volumes of spleen extracts). 
The preparations were tested against an equal volume  (0.05  ml of a  2.5% suspension of 
A/Jax erythroeytes and left 1 hr at 37°C. CBA erythrocytes were used as control suspension. 
Fractionation of Pooled Sera.--Three pools of CBA sera (10 nil each) were fractionated on 
diethylaminoethyl (DEAE)-cellulose columns: normal CBA sera, pool II from tolerant mice, 
and sera from mice immunized against A/Jax living spleen cells (five injections of 12 X  l0  s 
cells over a period of 2~  months). 
Column chromatography was made on DEAE-cellulose with a continuous and linear gradi- 
ent of NaC1 (0.02-1 M) in pH 8  tris(hydroxymethyl)aminomethane buffer, and 20 fractions 
were obtained (from slowest IgG's to albumin). Cold ethanol fractionation of serum pool III 
was performed according to Deutsch (20). The method was studied and modified to be applied 
to mouse sera, especially to fractionate immunoglobulins into slow and fast (electrophoretie) 
ones. It includes treatment with 25% cold (-- 10°C)  ethanol and precipitations by pH adjust- 
ments at 7.7, 5.5, and 7.4 in succession giving rise to three sediments and three supernatants. 
The first and third supernatants, as well as the second and third sediments, are kept for anal- 
ysis and study. 
Immunodiffusion in Gel Analysis of Fractions  and Sera.--Qualitative analysis was made 
through miero-Ouchterlony on cover slips (1% agar in 9% NaCI) and microimmunoeleetro- 
phoresis on histological slides (1% agar in Veronal buffer, 0.05 M, pH 8.6). Monospecific (anti- 
IgM, anti-IgA, anti-IgG1, anti-IgG2) and plurispecific anti-mouse immunoglobulins and sera 
were used. 
Semiquanfitative analysis for immunoglobulin classes was made through Mancini's method 
of radial immunodiffusion, utilizing the same monospecific immune sera (21).  The calibration 
was realized with pure normal  IgG2  (without discrimination between  IgG~a  and  IgC-2b), 
with IgG1 and IgA from myeloma, and IgM from Sephadex G-200 first peak.  The obtained 
figures are  expressed  in milligram per milliliter for sake of clarity, but knowing  that they 
actually are expressions of relative values. For normal CBA serum they were found intermedi- 
ate (as a whole) between those found by Fahey and Barth in C3H/He and C57BL/6NJ (22) 
and by Fahey and Sell (23) in NIH-WS mice (23). 
Immuno-Sero-Biological Tests of Sera  and their Fractions.--The following tests were per- 
formed: hemagglufination according to Gofer and Mikulska (24); synergistic hemagglutination 
according to Gorer et al. (25), slightly modified (undiluted studied preparation is mixed with 
doubling dilutions of a  standard CBA anti-A immune serum prediluted in such a  way as to 
give three positive wells with A  erythrocytes when mixed with control serum or fraction); 
cytotoxic activity, slightly modified from Chouroulinkov et al.  (26); hemolytic activity, ac- 
cording to Hildemann (27); passive cutaneous anaphylaxis (PCA) 1 according to Kinsky et al. 
(28). 
Evaluation of Facilitation-Enhancing  Properties of Sera.--6 >( 106 cells of SaI were injected 
subcutaneously into the right flank of each CBA male recipient. Recipients were injected intra- 
venously the day before with 0.4 ml of serum. Two control groups received either normal CBA 
serum (NS)  or CBA anti-A serum (IS)  diluted 1/~. The latter was prepared in CBA animals 
1 A bbreviatlons used in this paper: NS, normal serum; PCA, passive cutaneous anaphylaxis; 
SaI, A/Jax sarcoma I; Sa 15091a,  A/Jax sarcoma 15091a. 1188  FACILITATING  ANTIBODIES  IN  LIVING  CELL  TOLERANCE 
which have received five injections of living A spleen cells within a perio  d of 3 months. A strong 
enhancing activity was assessed for this serum in a preliminary trial. 
Three groups of ten animals received serum pools I, II, and III, respectively.  Mean tumor 
diameters were measured every 5 days and the day of the recipient's death recorded. Mortality 
curves were plotted in probit units on a  logarithm time scale  giving  almost straight lines. 
The rate of death was expressed by the slope of each line. 
RESULTS 
Properties  of Sera from Highly  Tolerant  Mice  (Compared with Normal and 
Immune Sera).--Sera were taken from the same CBA mice highly tolerant to 
A/Jax  (see  Materials and  Methods  and  Fig.  1)  at  three  different periods of 
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FIO. 2.  Content of CBA sera (from normal, immune, or tolerant mice) in immunoglobulins 
of four different classes. Semiquantitation was  done according to Mancini's technique.  Non- 
complement-fixing immunoglobulins (IgG1 and IgA) are higher in tolerant sera that in normal 
ones. Complement-fixing immunoglobulins  (IgG2 and IgM) are not elevated. 
tolerance: before skin graft test for tolerance (pool I), between days 14 and 80 
after this test (pool II), and at time of sacrifice with a  perfect graft (pool III) 
120 days after grafting. All three were studied for serological  and biological proper- 
ties and compared with a  pool of normal  CBA sera and  another pool of CBA 
immune sera anti-A/Jax. 
Content in  immunoglobulins  of four  classes:  Semiquantitative  analysis  ac- 
cording to  Mancini's technique  with  monospecific anti-IgM,  IgA, IgG1,  and 
IgG2 (without distinguishing between G2~ and G2b) allows an approximate value 
for the content in immunoglobulins of these four clases (Fig. 2). It must be first 
noticed that,  as a  whole the evaluated content of tolerant pool II in immuno- 
globulins is about  130%  that of normal CBA serum pool, while immune CBA 
serum pool is 160%  that of normal (normal 6.96 mg/ml, tolerant 9.00 mg/ml, 
and immune 11.24 mg/ml). The most striking feature is that the serum richest G.  A.  VOISIN,  R.  G.  KINSKY,  AND  I-I.  T.  DUC  1189 
in IgG1 is the tolerant one (3.10 mg/ml)  followed by the immune serum  (2.7 
mg/ml) and by the normal one (2 mg/ml). For IgA, the tolerant serum  concen- 
trations are intermediate between that of immune and normal sera, being below 
the former and above the latter.  Finally,  complement-fixing immunoglobulins 
(IgM and IgG2) in tolerant sara are lower than in immune ones and comparable 
to those in normal sara. 
Serological  activities:  The  serological  and  PCA  activities  of  the  five  sera 
(normal, immune, and the three tolerant pools) are simply sunmlarized in Table 
I  where  it may be noticed  that while immune  serum had strong hemaggluti- 
nating, hemolytic, and anaphylactic activity and normal serum (as control) had 
no detected activity, the three pools from highly tolerant animals presented (as 
TABLE I 
Serological Activity of CBA Sara (from Immune,  Normal, and Tolerant Mice) 
Passive 
Origin of  serum  Direct  Synergistic  Hemolysis  cutaneous 
hemagglutination  hemagglutination  anaphylaxis 
CBA immune to A  260,000*  N.D.$  66%§  +++ 
Normal CBA  .... 
CBA tolerant  of A 
Pool I  (before grafting)  --  -t-3 dilutions  --  -- 
Pool II (14-80 days af-  --  + 1 dilution  --  -- 
tar grafting) 
Pool III (time of sacri-  --  +4 dilutions  --  -- 
rice) 
* Reverse of titer. 
N.D.  =  not done. 
§ Maximum percentage of hemolysis. 
already described)  synergistic hemagglutinating activity. This was less marked 
after skin graft (pool II), conceivably due to antibody absorption on the graft. 
In  vivo facilitation-enhancing  activity:  A/Jax  SaI  tumors  grafted  in  CBA 
mice have a  facilitated  take and enhanced growth by treating  recipients with 
sara either immune anti-A or tolerant of A  (from any of the three pools) as com- 
pared  with  animals  treated  with  normal  CBA sara,  showing  the  presence  of 
facilitation-enhancing antibodies at various periods of high tolerance before and 
after skin grafting. The facilitating activity is shown both by the earlier deaths 
and by their increased proportion in recipients treated with immune or tolerant 
sara (Table II and Fig. 3). 
Furthermore if the growth curves of the only lethal tumors are compared in 
the five groups (this can be done since there are some lethal  takes even  in the 
normal  serum-treated  controls),  the following may be  noticed  (Fig.  4):  mice 
injected with normal serum have a strong and early rejection reaction beginning 
after day 10, leading to an almost complete disappearance of palpable tumors, 1190  FACILITATING  ANTIBODIES  IN  LIVING  CELL  TOLERANCE 
and ending around d~ys 20-25; while animals injected with immune serum have 
a later, weaker, and shorter rejection reaction not leading  to complete disap- 
pearance of palpable tumors, beginning  after day 20 and ending  around days 
25-30. The situation is strikingly intermediate for animals injected with tolerant 
sera of the three pools. 
TABLE  II 
Passive Enhancement Facilitation of Allografted  SaI Cells with Sera from 
Highly Tolerant Animals 
Origin of serum 
Propor-  (Significance of  Propor-  tion of  tion of  difference  to  deaths 
lethal  normal serum 
tumors  group)  on day  65* 
(Significance of  Har-  (Significance of  monic  difference  to  MST~:  of  difference  to 
normal serum  normal serum  group)  grafted  group) 
animals 
days 
Normal CBA  4/10  0/10  197 
CBA tolerant of A 
Pool I  (before  graft-  5/5  (P~ 0.05)  1/5  (NS)  73  (P~  0.02) 
ing) 
PoollI (14-80 days af-  9/10  (P~  0.05)  6/10  (P~  0.01)  60  (P~, 0.01) 
ter grafting) 
Pool III (time of sac-  9/10  (P~<  0.05)  7/10  (P~,< 0.005)  56  (P~  0.02) 
rifice) 
CBA immune to A  4/5  (NS)  4/5  (P~  0.005)  54  (P~  0.02) 
* All control animals surviving on that day. SaI ceils are injected in CBA mice having received CBA serum 
from mice either normal, tolerant of A, or immune to A. They are followed for their survival time. 
MST =  mean survival time. 
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Fro.  3.  Cumulative mortality curves of CBA mice grafted with A/Jax  sarcoma SaI and 
injected with sera from CBA mice (either normal, immune, or tolerant). Prob-log scales (per- 
centages of mortality in probit units, survival time in logarithms" of  days),  allowing drawing 
of mortality curves in straight lines. The onsets and the slopes of the curves, as well as the final 
death percentages, deserve attention. CG  =  center of gravity of the curves (points of coordi- 
nates x, y).  (x) indicates a point 0%  (pool I) that would, in probit scale, be placed at the  infi- 
nite position on the curve. G.  A.  VOISIN~  R.  O.  KINSKY~ AND  H.  T.  DUC  1191 
Finally,  when  comparing the  growth curves on nonlethal  (finally rejected) 
tumors in  the  various groups,  the  following may be  seen:  in  normal  serum- 
treated mice initial growths occurred up to day 10, reaching l0 mm in diameter 
with complete regression (no palpable tumor) after day 15. In immune serum- 
treated animals,  the only survivor had a  tumor of maximum size (19 ram) on 
days  15-20  with  complete  regression  after  day 45.  In  tolerant  sera-treated 
animals  (pools II and  III, no survivors with pool I),  the  two survivors had 
tumors of maximum diameter (10-12 ram) on day 10 with complete regression 
on days 20-25  (that is 5-10 days later than with normal serum). Thus, even in 
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FIR.  4.  Growth  curves of allografted A/Jax sarcoma I  giving lethal takes on CBA mice 
treated with sera from CBA mice (either normal, anti-A, or tolerant of A). Only lethal tumors 
are taken into account in these curves. There are striking differences  in the rate of progression 
as well as in the time and intensity of the rejection reaction, according to the treatment  of 
the hosts. 
surviving animals, a difference was observed indicating a facilitation-enhancing 
action of immune and of tolerant sera. 
No significant difference has been found between the facilitating activities of 
the three pools of tolerant sera: pool I  (pregraft), II (postgraft), and III (exsan- 
guination). The centers of gravity of the cumulative mortality curves of Fig. 3 
(points with coordinates equal  to  the  means  of  the  experimental  points  of 
the same curve) are strikingly close for the three pools 
Specificity  of facilitating  activity  in  tolerant  sera:  Enhancing  activity  was 
tested  in  Sa  15091a  grafted  on  CBA  mice. This  tumor proved in  previous 
trials to be highly specific for A strain (with 55 rejections in 20 days out of 55 
CBA mice injected with 4-6 million tumor cells). Three aliquots of 5 ml of the 
same tolerant serum (CBA tolerant of A) were either left untreated or absorbed 
30 Tin at 37°C with 1 ml of packed sarcoma cells or "pseudoabsorbed"  in sim- 
ilar  conditions  with  CBA  spleen  cells.  They  were  passed  through  Sephadex 1192  FACILITATING ANTIBODIES  IN  LIVING CELL  TOLERANCE 
G-200 column (Pharmacia Fine Chemicals Inc., Uppsala, Sweden) and the con- 
centrated  immunoglobulin-contalning  fractions  (as  well  as  similar  fractions 
from normal CBA serum) were injected into CBA mice grafted 24 hr later with 
Sa  1509Is.  In  17  unabsorbed  tolerant  serum fractions-treated  animals,  two 
lethal takes were observed, as in 2 of 18 animals treated with pseudoabsorbed 
tolerant serum fractions; complete rejections were observed in all of 18  mice 
injected with specifically absorbed tolerant serum fractions as well as in 16 mice 
injected with similar fractions from normal  CBA serum. The over-all results 
were therefore 11% lethal takes in 35 mice injected with unabsorbed or pseudo- 
absorbed tolerant serum fractions vs. 0 % in 89 mice (18 injected with absorbed 
tolerant fractions  and  71  injected with  either normal  CBA serum or normal 
CBA fractions). The difference between these  two groups is significant (P  < 
O.Ol). 
TABLE  III 
Presence of Hemagglutinating Antibodies (Direct Hemagglutination) Extracted from Spleen of 
Tolerant Mice 
No. of mice with specific hemagglutinating activity and its degree* 
Total 
Immune status of CBA mice  No. of  Positive 
mice  Negative 
+  ++  +++  ++++ 
Tolerant of A  59  47  (80%)  4  3  4  1 
Normal  20  20  0  0  0  0 
Immune to A  5  0  0  0  0  5 
* Spleen extracts of these CBA mice were tested against A/Jax erythrocytes for hemag- 
glutinating activity. CBA erythrocytes were used as negative controls. 
Extraction  of Antibodies from Spleens of Highly Tolerant Mice Compared with 
Normal and  Immune Mice.--59  spleens from exsanguinated,  highly  tolerant 
mice, taken at day 120 of tolerance, were individually treated by procedures of 
concentrated extraction and of moderate heat elution (see Materials and Meth- 
ods). They yielded 59 preparations, 20 % of which were able to give some degree 
of direct hemagglutination  (Table III). Although  no absorption experiments 
could be performed, negative controls were represented, by spleens from normal 
CBA mice, and positive controls by spleens taken since day 5 after immuniza- 
tion of CBA mice against A/Jax by means of either spleen cells or skin grafts. 
Furthermore, all these spleen extracts (from CBA mice either  normal,  tolerant 
of A  or immune to A) were negative when tested against CBA mice erythro- 
cytes. Therefore, while  direct hemagglutinating antibodies were not found in 
sera of these highly CBA tolerant mice, some could be extracted from one out 
of five of the spleens of the same animals. 
Properties  of Chromatographic Fractions from Sera  of Highly  Tolerant  Mice 
(Compared with Normal and Immune Sera).--Three pools of sara were chosen G.  A.  VOISIN,  R.  G.  KINSKY,  AND  H.  T.  DUC  1193 
for fractio aation among the five that were studied above for their various ac- 
tivities:  immune serum pool,  normal serum pool,  and  tolerant serum pool II 
(the most abundant). 
Immune and normal pooled sera gave the expected elution profiles (Fig. 5) 
and immunoglobulin  classes distribution  (Fig. 6).  Also expected was the  dis- 
tribution of serological activities of immune fractions: complement-fixing anti- 
bodies (IgG2) first eluted and hemagglutinating antibodies eluted on a  broad 
range of molarities. Furthermore anaphylactic activity (passive cutaneous ana- 
phylaxis) was found mainly in fractions 4  to 11, as analyzed elsewhere (28). 
FIG. 5.  DEAE fractionation of CBA sera (immune to A, tolerant of A, and normal). Elu- 
tion profiles and properties. 
As expected,  no activity whatsoever was found in  fractions of normal  sera 
thus insuring that activities eventually found in fractions of tolerant sera were 
not artifactual, even if not found in the whole sera before fractionation. 
In tolerant serum pool II,  the findings were as follows: 
Elution profiles and immunoglobulin  contents (of the four classes):  The elution 
profile wa,s not different from those of the normal and immune sera (Fig. 5). 
The immunoglobulin content of the fractions, however, was different (Fig. 6) : 
the IgG2 profile was as moderate as the one for normal serum while it dominated 
the profile of the immune serum in every single fraction (with a rebound of fast 
anionic IgG2, which later proved to be IgG~b). IgG1, however, dominated most 
of the profile of the tolerant serum, except for the less anionic part (with IgG2 
predominating in the first four fractions) and the most anionic part where IgA 1194  FACILITATING  ANTIBODIES  IN  LIVING  CELL  TOLERANCE 
FIo. 6.  Immunoglobulin content of CBA sera fractions from immune, tolerant, or normal 
mice. 
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FIG.  7.  Immunoglobulin content (of four classes), synergistic hemagglutination, and facil- 
itation-enhancing properties of tolerant sera DEAE fractions. G.  A.  VOISIN, R.  G.  KINSKY, AND YI.  T.  DUC  1195 
dominated. In contradistinction, IgG1 did not dominate in normal and immune 
sera,  and their profiles were rather similar to each other. This was,  to a  lesser 
extent, also the case for IgA. Nothing remarkable was seen for IgiV[ except that 
it was less prominent in tolerant than in immune fractions. 
Immuno-serological  activities of fractions (Fig. 5):  Two properties, absent in 
the  unfractionated  tolerant  sera,  appeared:  a weak specific immune hemolysis 
( < 20 %) in two cationic fractions of IgG2 and a weak direct hemagglutination 
in IgG2  +  IgG1 fractions.  Synergistic hemagglutination,  detected  in unfrac- 
tionated serum, was localized in fast anionic globulins with a curve of intensity 
paralleled by the one of IgA concentration (Fig. 7). Tolerant fractions gave no 
anaphylactic activity except for a limited one at the peak of IgG1 concentration. 
TABLE IV 
Biological Activities of Antibodies in Cold Ethanol Fractions of Pool 111 Tolerant Sera 
(CBA Tolerant of A) 
Facili- 
Fractions  Predominant immunoglobulin  class  HA  HL ac-  PCAac.  tatlon-  titer  tivity tivity enhancing 
activity 
% 
First supernatant  (pH  IgG1  (as  contaminant,  fraction  es-  0  0  +  -- 
7.7)  sentially  albuminic  and  a-globu- 
linic) 
Second  sediment  (pH  Mixed (mainly/~-globulins)  64  0  --  -- 
5.5) 
Third supernatant (pH  IgG1  16  24  +  -4- 
7.4) 
Third  sediment  (pH  IgG2  32  30  --  -- 
7.4) 
HA  =  Hemagglutination  (reverse of titer); HL  =  hemolysis  (maximum percentage  of 
hemolysis). 
Facilitating activity:  This was tested by looking for enhanced growth of Sa 
15091a  grafted  in  CBA mice injected with serum fraction. This sarcoma pre- 
sents no take in normal CBA mice but is less susceptible to enhancement than 
SaI. A moderate but definite action was found by comparing the tumor growth. 
This facilitating action was found linked to synergic hemagglutination activity 
of the fractions, as well as to the presence of IgA (P <  0.001), and not to that 
of IgG2, IgG1, or IgM (Fig. 7). This is at variance with what is usually found 
in immune sera where the facilitating action has been found in close agreement 
with anaphylactic IgG1 antibodies  (these experiments and reference 28). 
Cold  ethanol fractionation  of pool III:  Tolerant  sera,  pool  III, were  frac- 
tionated  according to Deutsch's technique  and examined for their content in 
immunoglobulins and serological activity. It has been found (Table  IV)  that 
IgGl-containing  fractions  had  PCA  activity,  IgG2-containing fractions  had 1196  FACILITATING ANTIBODIES  IN  LIVING CELL  TOLERANCE 
hemolytic activity, and that the second sediment (at pH 5.0)  devoid of both 
PCA and hemolytic activity still had a clear hemagglutinating activity (1/64). 
Facilitation-enhancing  activity on  SaI tumor  growth  on  CBA recipients was 
detected in IgGl-rich third supernatant that also presented a moderate hemag- 
glutinating activity and some degree of hemolytic activity. The specificity of 
these  serological reactions was  controlled as  follows: no activity whatsoever 
was  found  on  CBA  erythrocytes and  local  increased  vascular  permeability 
(PCA) was only observed at the time when, and only if, A/Jax antigen is in- 
jected intravenously. 
DISCUSSION 
The main elements brought out by these experiments which will be discussed 
are the following: the continuous presence of facilitation-enhancing antibodies 
in sera from tolerant animals; the character of high tolerance of all animals of 
which the sera were studied; the presence in fractions and extracts of immune 
activities absent in whole sera from tolerant animals;  the particular immuno- 
globulin class profile of tolerant sera as compared with normal and immune ones; 
the double link between synergic hemagglutination, IgA immunoglobulins, and 
facilitating propelties. These elements raise several problems, such as the nature 
of the responsible antibodies and the relations between tolerance and facilita- 
tion. 
Continuous Presence  of Facilitating Antibodies in  the Sera  of Tolerant Ani- 
mals.--The presence of facilitation-enhancing antibodies in the sera of tolerant 
animals  had  already been described and their specificity demonstrated (1, 2), 
but their evolution has been followed here from 28 days after birth to almost 6 
months (time of sacrifice)  by means of the  three pools of sera: pool I  (pretest 
graft), pool II (posttest graft), and pool III (sacrifice). Facilitating antibodies, 
as well as antibodies responsible for synergic hemagglutination, have been seen 
to be continuously present. No striking differences were found in the properties 
of the three pools. Small differences were still noticed such as a depression in 
synergic hemagglutinins in pool II as compared with I  and III (Table I). This 
might be due to fixation on skin graft antigens. Also the enhancing activity for 
tumor growth was almost identical for pools II and III while in pool I it m~ni- 
rested itself later, more rapidly, and more completely (100 % lethal growth; Fig. 
3). Finally, the properties of pool III looked in several circumstances relatively 
closer to those of immune sera than did the other two pools, for instance, in the 
growth kinetics of tumors enhanced by pool III (Fig. 4)  or by the presence of 
hemolysins in cold ethanol fractions of pool III. The specificity of these facil- 
itating antibodies, already demonstrated (1, 2), have been confirmed again by 
absorption  experiments. The continuous presence of  these  antibodies  in  the 
animals studied excludes the possibility that they would represent the beginning 
of an interruption of tolerance. This is even more strongly excluded  by  the  fol- 
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Character of High  Tolerance of all Animals Studied.--Only  sera from highly 
tolerant animals entered the three pools. The criteria for high tolerance were 
most severe: perfect state of skin graft (looking like isografts) during the life of 
the animals, including the day of sacrifice. These criteria were already met in 
the preceding experiments (1,  2).  Another  criterium of high  tolerance  is also 
fulfilled in these experiments: total absence of circulating antibodies detected 
in the sera by classical tests of hemagglutination,  cytotoxicity, and hemolysis 
(direct hemagglutinins were sometimes found during preceding experiments in 
sera from otherwise highly tolerant mice [1, 2]). The very demonstration of facil- 
itating antibodies in the sera of highly tolerant animals shows an actual transfer 
of tolerance towards the corresponding antigenic cells. 
Presence in Fractions  and Extracts of Immune  Activities that  are Absent in 
Whole Tolerant  Sera.--While  direct anti-A hemagglutinins were not found in 
whole unfractionated sera of the highly tolerant animals, they were  found  in 
three  preparations made from these animals:  in 20 % of the spleen eluates, in 
DEAE fractions, and in cold ethanol fractions (in both cases in IgG1- and IgG2- 
containing fractions). Even a  small amount of hemolysis was found in IgG2- 
containing DEAE fractions of pool II tolerant sera and cold ethanol fractions 
of pool III tolerant sera. The cause of the absence of expression of these anti- 
bodies in unfractionated sera is not some nonspecific inhibitor as is shown by the 
fact that mixing equal volumes of positive fractions with whole tolerant serum 
led not to inhibition but to an increased hemagglutination titer  (synergic ac- 
tion). The possibility remains, but has not been explored, that different frac- 
tionated classes of antibody exert a competitive action. 
Particular Immunoglobulin  Class  Profile  of Tolerant  Sera as Compared  with 
Normal Ones and with Immune Ones.--Schematically,  tolerant sera are close to 
immune ones for noncomplement-fixing immunoglobulins IgG1 and IgA, while 
for complement-fixing immunoglobulins IgM and IgG2 they are close to non- 
immune, normal sera. Indeed pool II, studied for its content in immunoglob- 
ulins, was found to contain 155 % as much IgG1 and 189% IgA, but only 95 % 
IgM and 107 % IgG2 as pooled serum from normal mice. This elevation of the 
serum content in immunoglobulins of certain classes is taken as an indication 
that specific antibodies of the same classes are probably increased, while anti- 
bodies of unelevated classes would  not be increased.  This is in keeping with 
views discussed further below on the relations between tolerance and facilitation 
and on the nature of responsible antibodies. 
Link between Synergistic Hemagglutinins,  IgA, and Facilitating Antibodies.- 
Synergistic hemagglutinins (antibodies unable to cause direct hemagglutination 
but increasing the hemagglutinating titer of a  reference immune serum)  have 
been detected in more than two-thirds of tolerant sera (1,  2). They are again 
found in the three pools of tolerant sera.  Synergistic hemagglutination  seems 
to be a special manifestation of antibody activity, possibly due to a particular 
immunoglobulin.  Indeed,  a  link  between  synergistic hemagglutinins  and  the 1198  FACILITATING ANTIBODIES  IN  LIVING  CELL  TOLERANCE 
presence of IgA, already suggested in electrophoretic fractions of immune IC 
anti-A serum (29), was demonstrated (P <  0.001) in DEAE chromatography 
fractions of pool III  tolerant sera  (CBA tolerant of A)  (Fig. 7). Further links 
were suggested in certain cases between facilitation-enhancing properties  and 
the presence of IgA as well as synergistic hemagglutinins in fractions of immune 
sera (29, 30). Finally a link between tolerance and the presence of synergistic 
hemagglutinins was suggested (1, 2). The earlier findings and suggestions were 
confirmed and correlated by the present description of a highly significant link 
between the presence of IgA, synergistic hemagglutinins, and facilitating prop- 
erties in fractions of sera from highly tolerant mice (Fig.  7). This makes con- 
ceivable the possibility that antibodies of the IgA class responsible for syner- 
gistic hemagglutination  would play a  role in  the mechanism  of tolerance of 
living cells. 
Facilitating antibodies responsible for tumor growth present in transplanta- 
tion immune sera have however been found linked to IgG1  and anaphylactic 
properties in the same CBA-A combination (31), although a link with IgA and 
synergistic hemagglutination was suggested in the IC-A combination. In any 
event, the responsible antibodies were localized in the electrophoretically fast 
migrating (29, 30) and DEAE gradient nonearly eluted fractions (31) also char- 
acterized  by  their  content  in  noncomplement-fixing antibodies.  Electropho- 
retically slow migrating antibodies were found to be rather inhibitory for tumor 
grafts (except when sufficiently diluted). These results were also in agreement 
with similar results by Chard (32) and Chard et al. (33). The main discrepancy 
is  with  the  authors who  find  the  facilitation-enhancing activity localized in 
complement-fixing, cytotoxic IgG2 antibodies (34, 35). Incidentally, enhancing 
properties have several times been seen in this laboratory to occur also in frac- 
tions apparently containing only IgG2 (especially IgG~) antibodies,  especially 
when they are diluted. One must therefore consider that either different parts 
of the phenomenon (such as central immunodeviation vs. peripheral blockade) 
are due to different immunoglobulins (36), that the responsible  antibodies be- 
long to another class of immunoglobulin which is not similarly fractionated in 
the different systems, or that several immunoglobulins may play a  role  when 
they are in certain proportions, as suggested by Linscott's experiments  (37) for 
peripheral protection. These proportions would be obtained in different fractions 
for different systems. 
Relation  between  Tolerance  and Facilitation  Enhancement.--It  is  interesting 
that antibodies, especially of a particular type (synergistic hemagglutinins), are 
present in sera of tolerant mice. It is more interesting that they are continuously 
present in the sera of highly tolerant animals and that they are related to the 
state of tolerance (see above and Voisin et al. [1, 2]) and not due to a state of 
incomplete tolerance or due to a beginning interruption of tolerance. But it is 
even more interesting that they have facilitating properties, allowing the take 
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that the phenomenon is an active immunological response (of a special type re- 
lated  to  the  facilitation-enhancement phenomenon). This hypothesis has  al- 
ready been put forward (1, 2, 16, 17) and experimental support has been brought 
to it by the following facts: (a) Active and passive procedures of facilitation may 
lead  to  a  state  of specific depression of immune  reactivity indistinguishable 
from that of immunological tolerance in the graft-versus-host situation (5, 7, 9) 
and in immune reactions towards sheep red blood cells (16,  17).  (b) Lymphoid 
tissues of animals tolerant of allogeneic cells are in a state of reactivity closer 
to that of the immune state than of normal animals as shown for pyroninophilia, 
immunoglobulin  synthesis,  and  specific graft-versus-host  reactivity  in  some 
combinations (3, 10). (c) Specific antibodies exist in highly tolerant animal sera 
such  as  synergistic hemagglutinins.  Some are fixed on presumably  tolerated 
cells as shown by immunofluorescence and hemagglutination (1, 2). (d) Passive 
transfer of tolerance can be realized by serum from highly tolerant animals pro- 
vided one utilizes a sensitive system (1, 2, 25,  and this paper). Work in other 
laboratories has also substantiated  the preceding hypothesis by showing that 
states of tolerance can be adoptively transferred (38-40), that antibodies may 
help or allow the in vitro induction of tolerance (11, 41), and that the presence 
of sensitized cells,  as well  as counteracting serological properties, inhibit the 
destructive action of cells in animals made tolerant at birth (14), after irradia- 
tion repopulation (13), or even in allophenic mice (18). 
If immune tolerance results from an active immune response, one may wonder 
about the mechanism and the reasons for the usually observed differences be- 
tween classical facilitation (with circulating antibodies) and classical  tolerance 
(without circulating antibodies), as well as the inertia of lymphoid cells from 
tolerant animals  in graft-versus-host  or mixed lymphocyte culture  situations 
(42, 43). It is not inconceivable and in keeping with the present results, as well 
as others (1, 2,  4, 6,  44-47),  that "immunodeviation" (split tolerance) is the 
intermediary step between classical enhancement facilitation and classical tol- 
erance. It combines the depression of both cellular hypersensitivity and com- 
plement-fLxing antibodies with  conservation or elevation of noncomplement- 
fixing antibodies. Even the later could be progressively depressed due to lack 
of helper cells as discussed elsewhere (19). 
SUMMARY 
CBA  mice were rendered highly tolerant  to A/Jax cells  by neonatal intra- 
venous injections  of (CBA X  A)FI spleen cells.  The high degree of tolerance 
was ascertained  by the absence of circulating  antibodies  detected in the sera  by 
the usual tests  and by the perfect  state  of A  skin  grafts  during all the experi- 
ments. Tolerant sera  (sera  from tolerant  animals) were studied at three  periods 
of tolerance: before skin test grafting, from 2 to 11 wk after grafting, and at 
time of sacrifice at almost 6 months of age. 
The tolerant sera were shown to have specific facilitation-enhancing proper- 1200  FACILITATING ANTIBODIES  IN  LIVING  CELL  TOLERANCE 
ties promoting the  take and  growth  of A/Jax sarcoma  (SaI  and  /Sa  15091a 
grafted on normal CBA mice. These  properties  were  present  throughout  the 
duration of the experiments, showing that they were not the result of a  begin- 
ning interruption of tolerance. The tolerant  sara,  although  lacking  the  usual 
serological properties (hemagglutination,  hemolysis,  cytotoxicity,  passive  cu- 
taneous  anaphylaxis)  had,  however,  specific  synergistic  hemagglutinating 
properties  (increasing the hemagglutinating titer of a reference immune serum). 
Antibodies  giving  direct  specifc  hemagglutination  could  be  extracted  from 
spleens of 20% of highly tolerant  mice.  The  tolerant  sara  were  also  found  to 
contain more IgG1 and more IgA than normal sara while they contained normal 
quantities of the complement-fixing immunoglobulins IgG2 and IgYl. 
Fractionation of tolerant sara on DEAE chromatography column confirmed 
the  data concerning immunoglobulin classes and demonstrated direct specific 
serological activities undetected in unfractionated sara: a weak hemolysis in the 
most cationic fractions and a weak hemagglutination in the middle fractions. 
Synergistic hemagglutination,  detected in unfractionated serum, was localized 
in fast anionic fractions containing  high IgA concentration,  along with facil- 
itation-enhancing activity, thus confirming a link suggested previously between 
these three properties. 
The  relation  between  immunological  tolerance  and  facilitating  antibodies 
was discussed in the light of the fact that antibodies, possibly of a particular 
class continuously present at low dose in the sara of highly tolerant animals, 
are able to transfer (at least partly) this state of tolerance provided a sensitive 
test system is utilized. 
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